<VariationArchive RecordType="classified" VariationID="830490" VariationName="NC_000001.11:g.(?_193122201)_(193250712_?)del" VariationType="Deletion" Accession="VCV000830490" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-03-26" DateCreated="2020-04-15" MostRecentSubmission="2023-03-26">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="818884" VariationID="830490">
      <GeneList>
        <Gene Symbol="B3GALT2" FullName="beta-1,3-galactosyltransferase 2" GeneID="8707" HGNC_ID="HGNC:917" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>1q31.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="193178730" stop="193186613" display_start="193178730" display_stop="193186613" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="193147859" stop="193155742" display_start="193147859" display_stop="193155742" Strand="-" />
          </Location>
          <OMIM>603018</OMIM>
        </Gene>
        <Gene Symbol="CDC73" FullName="cell division cycle 73" GeneID="79577" HGNC_ID="HGNC:16783" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1q31.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="193122031" stop="193254815" display_start="193122031" display_stop="193254815" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="193091087" stop="193223944" display_start="193091087" display_stop="193223944" Strand="+" />
          </Location>
          <OMIM>607393</OMIM>
          <Haploinsufficiency last_evaluated="2022-04-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDC73">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-04-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDC73">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000001.11:g.(?_193122201)_(193250712_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1q31.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" innerStart="193091331" innerStop="193219842" display_start="193091331" display_stop="193219842" variantLength="128512" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.(?_193091331)_(193219842_?)del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.(?_193091331)_(193219842_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000001.11:g.(?_193122201)_(193250712_?)del AND Parathyroid carcinoma" Accession="RCV001031118" Version="2">
        <ClassifiedConditionList TraitSetID="834">
          <ClassifiedCondition DB="MedGen" ID="C0687150">Parathyroid carcinoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-08-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-08-24" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-15" MostRecentSubmission="2023-03-26">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12434154</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25444225</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29040582</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="834" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3270" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Parathyroid cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Parathyroid gland carcinoma</ElementValue>
                <XRef ID="MONDO:0012004" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CDC73-Related Parathyroid Carcinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Parathyroid carcinoma</ElementValue>
                <XRef ID="Parathyroid+carcinoma/5598" DB="Genetic Alliance" />
                <XRef ID="HP:0006780" DB="Human Phenotype Ontology" />
                <XRef ID="255037004" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PRTC</ElementValue>
                <XRef Type="MIM" ID="608266" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of CDC73-related disorders includes the following phenotypes: Hyperparathyroidism-jaw tumor (HPT-JT) syndrome. Primary hyperparathyroidism, the main finding of HPT-JT syndrome, occurs in up to 95% of affected individuals; onset is typically in late adolescence or early adulthood. HPT-JT-associated primary hyperparathyroidism is usually caused by a single parathyroid adenoma. In approximately 10%-15% of individuals, primary hyperparathyroidism is caused by parathyroid carcinoma. Ossifying fibromas of the mandible or maxilla, also known as cementifying fibromas and cemento-ossifying fibromas, occur in 30%-40% of individuals with HPT-JT syndrome. Although benign, these tumors can be locally aggressive and may continue to enlarge if not treated. Approximately 20% of individuals with HPT-JT syndrome have kidney lesions, most commonly cysts; renal hamartomas and (more rarely) Wilms tumor have also been reported. Benign and malignant uterine tumors appear to be common in women with HPT-JT syndrome. Parathyroid carcinoma. Most parathyroid carcinomas are functional, resulting in hyperparathyroidism and a high serum calcium level; however, nonfunctioning parathyroid carcinomas are also rarely described in individuals with a CDC73-related disorder. A germline CDC73 pathogenic variant has been identified in 20%-29% of individuals with apparently sporadic parathyroid carcinoma. Familial isolated hyperparathyroidism (FIHP). FIHP is characterized by primary hyperparathyroidism without other associated syndromic features. Individuals with CDC73-related FIHP tend to have a more severe clinical presentation and younger age of onset than individuals with FIHP in whom a CDC73 pathogenic variant has not been identified.</Attribute>
                <XRef ID="NBK3789" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7329" />
                <XRef ID="7329" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301744</ID>
                <ID Source="BookShelf">NBK3789</ID>
              </Citation>
              <XRef ID="143" DB="Orphanet" />
              <XRef ID="C0687150" DB="MedGen" />
              <XRef ID="MONDO:0012004" DB="MONDO" />
              <XRef Type="MIM" ID="608266" DB="OMIM" />
              <XRef Type="primary" ID="HP:0006780" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2355678" SubmissionDate="2023-03-21" DateLastUpdated="2023-03-26" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="NM_024529.4_Deletion (Entire Coding Sequence)|MedGen:C0687150" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001194424" DateUpdated="2023-03-26" DateCreated="2020-04-15" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12434154</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25444225</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29040582</ID>
          </Citation>
          <Comment>A gross deletion of the genomic region encompassing the full coding sequence of the CDC73 gene has been identified. Loss-of-function variants in CDC73 are known to be pathogenic (PMID: 12434154). The boundaries of this event are unknown as they extend beyond the assayed region for this gene and therefore may encompass additional genes. A similar copy number variant has been observed in individual(s) with hyperparathyroidism (PMID: 25444225, 29040582). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDC73" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.(?_193091331)_(193219842_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0687150" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12974844</SubmissionName>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2355678" TraitType="Disease" MappingType="XRef" MappingValue="C0687150" MappingRef="MedGen">
        <MedGen CUI="C0687150" Name="Parathyroid carcinoma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

